124 related articles for article (PubMed ID: 9343797)
1. Assessing uncertainty in cost-effectiveness analyses: application to a complex decision model.
Parmigiani G; Samsa GP; Ancukiewicz M; Lipscomb J; Hasselblad V; Matchar DB
Med Decis Making; 1997; 17(4):390-401. PubMed ID: 9343797
[TBL] [Abstract][Full Text] [Related]
2. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section.
Cooper NJ; Sutton AJ; Abrams KR
Stat Methods Med Res; 2002 Dec; 11(6):491-512. PubMed ID: 12516986
[TBL] [Abstract][Full Text] [Related]
3. Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis.
Stevenson MD; Oakley J; Chilcott JB
Med Decis Making; 2004; 24(1):89-100. PubMed ID: 15005958
[TBL] [Abstract][Full Text] [Related]
4. Measuring uncertainty in complex decision analysis models.
Parmigiani G
Stat Methods Med Res; 2002 Dec; 11(6):513-37. PubMed ID: 12516987
[TBL] [Abstract][Full Text] [Related]
5. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
Negrín MA; Vázquez-Polo FJ
J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation.
Gage BF; Cardinalli AB; Albers GW; Owens DK
JAMA; 1995 Dec; 274(23):1839-45. PubMed ID: 7500532
[TBL] [Abstract][Full Text] [Related]
7. Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantation.
Vanness DJ; Kim WR
Health Econ; 2002 Sep; 11(6):551-66. PubMed ID: 12203757
[TBL] [Abstract][Full Text] [Related]
8. Modeling the value for money of changing clinical practice change: a stochastic application in diabetes care.
Hoomans T; Abrams KR; Ament AJ; Evers SM; Severens JL
Med Care; 2009 Oct; 47(10):1053-61. PubMed ID: 19648827
[TBL] [Abstract][Full Text] [Related]
9. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z
Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of basiliximab induction in "old-to-old" kidney transplant programs: Bayesian estimation, simulation, and uncertainty analysis.
Emparan C; Wolters H; Laukötte M; Senninger N
Transplant Proc; 2005 Jun; 37(5):2069-71. PubMed ID: 15964341
[TBL] [Abstract][Full Text] [Related]
11. Enhancing value of information analyses.
Janssen MP; Koffijberg H
Value Health; 2009 Sep; 12(6):935-41. PubMed ID: 19432841
[TBL] [Abstract][Full Text] [Related]
12. Probabilistic cost-effectiveness analysis of HIV prevention. Comparing a Bayesian approach with traditional deterministic sensitivity analysis.
Johnson-Masotti AP; Laud PW; Hoffmann RG; Hayat MJ; Pinkerton SD
Eval Rev; 2001 Aug; 25(4):474-502. PubMed ID: 11480309
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective.
de Rooij M; Crienen S; Witjes JA; Barentsz JO; Rovers MM; Grutters JP
Eur Urol; 2014 Sep; 66(3):430-6. PubMed ID: 24377803
[TBL] [Abstract][Full Text] [Related]
14. Health economic studies: an introduction to cost-benefit, cost-effectiveness, and cost-utility analyses.
Angevine PD; Berven S
Spine (Phila Pa 1976); 2014 Oct; 39(22 Suppl 1):S9-15. PubMed ID: 25299265
[TBL] [Abstract][Full Text] [Related]
15. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
[TBL] [Abstract][Full Text] [Related]
16. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
[TBL] [Abstract][Full Text] [Related]
17. Indirect costs and cost-effectiveness analysis.
Ernst R
Value Health; 2006; 9(4):253-61. PubMed ID: 16903995
[TBL] [Abstract][Full Text] [Related]
18. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI).
Barton GR; Briggs AH; Fenwick EA
Value Health; 2008; 11(5):886-97. PubMed ID: 18489513
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
20. Need for speed: an efficient algorithm for calculation of single-parameter expected value of partial perfect information.
Sadatsafavi M; Bansback N; Zafari Z; Najafzadeh M; Marra C
Value Health; 2013; 16(2):438-48. PubMed ID: 23538197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
